RESUMO
Objetivo Evaluar la calidad de vida en pacientes diagnosticados de cáncer de vejiga no músculo invasivo a lo largo del estudio utilizando el cuestionario CAVICAVENMI. Material y Método Se incluyen 180 pacientes diagnosticados de TVNMI (febrero 2013 - junio 2015). Todos rellenaron el cuestionario CAVICAVENMI en cuatro ocasiones: previo a la cirugía y la primera, segunda y tercera visita postintervención. Aquellos que reciben tratamiento adyuvante completan el cuestionario en dos ocasiones más: a mitad y final del ciclo de tratamiento. Estudiamos la variabilidad en la calidad de vida con una T-Student para datos apareados. Realizamos T - Student para muestras independientes entre el decremento porcentual (antes de la intervención frente a tercera visita postintervención) y determinadas características tumorales (tamaño, número de siembras, localización y CIS - carcinoma in situ). Realizamos un estudio de regresión múltiple para determinar valores de confusión entre las características tumorales. Resultados Evidenciamos una mejora significativa en la calidad de vida a partir de la tercera visita postintervención en pacientes sin tratamiento adyuvante; y a partir del segundo momento postintervención en aquellos con tratamiento adyuvante. No existen diferencias significativas entre las características tumorales, pero observamos una mayor puntuación en presencia de las mismas. No encontramos factores de confusión. Conclusiones La calidad de vida en pacientes TVNMI, presenta una mejoría a lo largo del estudio. Esos cambios son más tempranos en los apartados de percepción de enfermedad, autoestima y estado emocional. Aquellos pacientes con presencia de las características tumorales estudiadas, presentan una peor calidad de vida, aunque no es estadísticamente significativo.
Purpose To evaluate the quality of life of patients diagnosed with NMIBC throughout the time of the study, using the CAVICAVENMI questionnaire. Material and Methods 180 patients diagnosed with NMIBC were included (February 2013 - June 2015) and completed the questionnaire on four occasions: prior to surgery, and in the first, second and third visits post-surgery. Patients on adjuvant treatment also completed it at the middle and final treatment cycle. Student's t-test was used to study the variability of the paired data in the quality of life questionnaire. An analysis (Student's-t Test) was made between the percentage decrease (before the intervention compared with the third post-surgery visit) and certain tumor characteristics (size, seeding number, location and carcinoma in situ) using. Multiple regression analysis was performed to determine confundant elements between tumor characteristics Result A statistically significant improvement in the quality of life was observed from the third post-intervention visit in patients that did not receive instillations, and in patients that received instillations, this significant improvement appeared from the second post-intervention visit. No statistically significant differences were found in the tumor characteristics, but a higher score was observed in the presence of these. We do not find confundant elements. Conclusions The quality of life in NMIBC patients showed an improvement throughout the study. These changes are seen earlier in the perception of the disease, in self-esteem and emotional state. Those patients with the presence of the tumor characteristics studied had a poorer, but not statistically significant, quality of life.
Assuntos
Humanos , Masculino , Feminino , Qualidade de Vida , Neoplasias da Bexiga Urinária , Carcinoma in Situ , Terapêutica , Bexiga Urinária , Análise de Regressão , NeoplasiasRESUMO
AIM: : The aim of this study is to check the ability of cerebrospinal fluid biomarkers of Alzheimer disease (CSF-BMK-AD) to make a discrimination checklist within a healthy group, according to their cognitive development at 2 years of obtaining the sample. MATERIALS AND METHODS: Between 2008 and 2010, 67 subjects without cognitive or behavioral disorders were included as a control group in a study on CSF-AD-BMK. Neuropsychological assessment at baseline and at follow-up had been carried out 2 years later. CSF was obtained at the inclusion. It was analyzed by Innotest reagents to measure amyloid-ß (Aß1-42), total-τ (T-τ), and phosphorylated τ181 (P-τ181p) protein levels, as well as T-τ/Aß1-42 and P-τ181p/Aß1-42 ratios. RESULTS: Two years after inclusion, 28 subjects were not able to be checked for cognitive evolution. Of those who were seen for follow-up (n=39), 29 were cognitively stable and 10 showed cognitive impairment. We found significant differences in Aß1-42 protein level (820 vs. 1359 pg/mL, P<0.003), in the T-τ/Aß1-42 ratio (0.40 vs. 0.19, P<0.009), and in the P-τ181p/Aß1-42 ratio (0.09 vs. 0.04, P<0.003) when both groups were compared. CONCLUSIONS: CSF-BMK-AD are able to discriminate between subjects in a group initially asymptomatic depending on their cognitive evolution at the 2 years' follow-up. These results are consistent with the decrease of CSF Aß1-42 protein levels as the first finding in preclinical AD showed.